REFERENCES
1. Gmeiner WH. Recent advances in therapeutic strategies to improve colorectal cancer treatment. Cancers. 2024;16:1029.
2. Gmeiner WH, Okechukwu CC. Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects. Cancer Drug Resist. 2023;6:257-72.
3. Rumpold H, Niedersüß-Beke D, Heiler C, et al. Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis. BMC Cancer. 2020;20:1149.
4. Gmeiner WH. Chemistry of fluorinated pyrimidines in the era of personalized medicine. Molecules. 2020;25:3438.
5. Wilson PM, Danenberg PV, Johnston PG, Lenz HJ, Ladner RD. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol. 2014;11:282-98.
6. Sen A, Karati D. An insight into thymidylate synthase inhibitor as anticancer agents: an explicative review. Naunyn Schmiedebergs Arch Pharmacol. 2024;397:5437-48.
7. Gmeiner WH. Novel chemical strategies for thymidylate synthase inhibition. Curr Med Chem. 2005;12:191-202.
8. Santi DV, McHenry CS, Raines RT, Ivanetich KM. Kinetics and thermodynamics of the interaction of 5-fluoro-2′-deoxyuridylate with thymidylate synthase. Biochemistry. 1987;26:8606-13.
9. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16:215-37.
10. Patel K, Yerram SR, Azad NA, Kern SE. A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing. Oncotarget. 2012;3:678-85.
11. Yang C, Xie LY, Windle JJ, Taylor SM, Moran RG. Humanizing mouse folate metabolism: conversion of the dual-promoter mouse folylpolyglutamate synthetase gene to the human single-promoter structure. FASEB J. 2014;28:1998-2008.
12. Epstein-Peterson ZD, Soff GA, Fenelus M, Korenstein D. Folate testing and deficiency in hospitalized cancer patients. Blood. 2018;132:5814.
13. Sobral AF, Cunha A, Silva V, Gil-Martins E, Silva R, Barbosa DJ. Unveiling the therapeutic potential of folate-dependent one-carbon metabolism in cancer and neurodegeneration. Int J Mol Sci. 2024;25:9339.
14. Taflin H, Odin E, Carlsson G, et al. Increased potentiation of 5-fluorouracil induced thymidylate synthase inhibition by 5,10-methylenetetrahydrofolate (arfolitixorin) compared to leucovorin in patients with colorectal liver metastases; The Modelle-001 Trial. BJC Rep. 2024;2:89.
15. Danenberg PV, Gustavsson B, Johnston P, et al. Folates as adjuvants to anticancer agents: chemical rationale and mechanism of action. Crit Rev Oncol Hematol. 2016;106:118-31.
16. Therizols G, Bash-Imam Z, Panthu B, et al. Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance. Nat Commun. 2022;13:173.
17. Mafi A, Hedayati N, Milasi YE, et al. The function and mechanism of circRNAs in 5-fluorouracil resistance in tumors: biological mechanisms and future potential. Pathol Res Pract. 2024;260:155457.
18. Barathan M, Zulpa AK, Ng SL, Lokanathan Y, Ng MH, Law JX. Innovative strategies to combat 5-fluorouracil resistance in colorectal cancer: the role of phytochemicals and extracellular vesicles. Int J Mol Sci. 2024;25:7470.
19. Matuszyk J. MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy. Mol Med. 2022;28:89.
20. Mori R, Ukai J, Tokumaru Y, Niwa Y, Futamura M. The mechanism underlying resistance to 5-fluorouracil and its reversal by the inhibition of thymidine phosphorylase in breast cancer cells. Oncol Lett. 2022;24:311.
21. Gmeiner WH, Dominijanni A, Haber AO, et al. Improved antitumor activity of the fluoropyrimidine polymer CF10 in preclinical colorectal cancer models through distinct mechanistic and pharmacologic properties. Mol Cancer Ther. 2021;20:553-63.
22. Haber AO, Jain A, Mani C, et al. AraC-FdUMP[10] is a next-generation fluoropyrimidine with potent antitumor activity in PDAC and synergy with PARG inhibition. Mol Cancer Res. 2021;19:565-72.
23. Okechukwu CC, Ma X, Sah N, Mani C, Palle K, Gmeiner WH. Enhanced therapeutic efficacy of the nanoscale fluoropyrimidine polymer CF10 in a rat colorectal cancer liver metastasis model. Cancers. 2024;16:1360.
24. Finan JM, Di Niro R, Park SY, et al. The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Cancer Biol Ther. 2024;25:2421584.
25. Liu J, Kolar C, Lawson TA, Gmeiner WH. Targeted drug delivery to chemoresistant cells: folic acid derivatization of FdUMP[10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells. J Org Chem. 2001;66:5655-63.
26. Chu E, Allegra CJ. The role of thymidylate synthase as an RNA binding protein. Bioessays. 1996;18:191-8.
27. Chu E, Koeller DM, Casey JL, et al. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci U S A. 1991;88:8977-81.
28. Chu E, Takechi T, Jones KL, et al. Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro. Mol Cell Biol. 1995;15:179-85.
30. Kugimiya N, Nishimoto A, Hosoyama T, et al. The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil resistance in human colon cancer cells. J Cell Mol Med. 2015;19:1569-81.
31. Gerard L, Gillet JP. The uniqueness of ABCB5 as a full transporter ABCB5FL and a half-transporter-like ABCB5β. Cancer Drug Resist. 2024;7:29.
32. Wilson BJ, Schatton T, Zhan Q, et al. ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res. 2011;71:5307-16.
33. Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N. 5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer Sci. 2020;111:3142-54.
34. Copur S, Aiba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol. 1995;49:1419-26.
35. Peters GJ, Backus HH, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta. 2002;1587:194-205.
36. Fischel JL, Formento P, Ciccolini J, et al. Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity. Br J Cancer. 2002;86:1162-8.
37. Zhu X, Li C, Gao Y, et al. The feedback loop of EFTUD2/c-MYC impedes chemotherapeutic efficacy by enhancing EFTUD2 transcription and stabilizing c-MYC protein in colorectal cancer. J Exp Clin Cancer Res. 2024;43:7.
38. Patel AG, Flatten KS, Peterson KL, et al. Immunodetection of human topoisomerase I-DNA covalent complexes. Nucleic Acids Res. 2016;44:2816-26.
39. Peters GJ, Smitskamp-Wilms E, Smid K, Pinedo HM, Jansen G. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions. Cancer Res. 1999;59:5529-35.
40. Liao ZY, Sordet O, Zhang HL, et al. A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes. Cancer Res. 2005;65:4844-51.
41. Gmeiner WH, Reinhold WC, Pommier Y. Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther. 2010;9:3105-14.
42. Very N, Hardivillé S, Decourcelle A, et al. Thymidylate synthase O-GlcNAcylation: a molecular mechanism of 5-FU sensitization in colorectal cancer. Oncogene. 2022;41:745-56.
